Literature DB >> 2690617

Comparative pharmacokinetics of ofloxacin and ciprofloxacin.

J S Wolfson1, D C Hooper.   

Abstract

Review of publications in which the pharmacokinetics of ofloxacin and ciprofloxacin were compared directly indicates that although similar in many respects, these fluoroquinolones exhibit three differences that may be important clinically. First, ofloxacin is more completely absorbed, achieves higher peak serum concentrations, and has a longer terminal elimination half-life, which result in a fivefold greater area under the curve than that of ciprofloxacin when similar doses are orally administered. Ofloxacin's more favorable pharmacokinetic profile seems to compensate at least in part for the greater activity of ciprofloxacin against gram-negative bacilli in vitro. Second, ofloxacin is eliminated almost entirely via the kidneys, whereas ciprofloxacin is eliminated via both the kidneys and non-renal routes. This suggests that ciprofloxacin may be preferable for patients with variable renal function, whereas ofloxacin may be preferable for patients receiving dialysis because of the need for less frequent administration. Third, concomitant use of ciprofloxacin with either theophylline or caffeine decreases elimination and thereby results in elevated serum concentrations of these methylxanthine derivatives. Because ofloxacin does not cause clinically significant alterations in the pharmacokinetics of either theophylline or caffeine, it may be preferable for patients using these concomitantly.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2690617

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  9 in total

Review 1.  Clinically significant drug interactions with cyclosporin. An update.

Authors:  C Campana; M B Regazzi; I Buggia; M Molinaro
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

2.  Five versus three days of ofloxacin therapy for traveler's diarrhea: a placebo-controlled study.

Authors:  H L DuPont; C D Ericsson; J J Mathewson; M W DuPont
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

Review 3.  Ofloxacin. A reappraisal of its antimicrobial activity, pharmacology and therapeutic use.

Authors:  P A Todd; D Faulds
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

4.  Oral absorption of ofloxacin administered together with aluminum.

Authors:  A Sánchez Navarro; M Martínez Cabarga; A Dominguez-Gil Hurlé
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

5.  The Role of Quinolones in Upper Respiratory Tract Infections.

Authors:  Ronald F. Grossman
Journal:  Curr Infect Dis Rep       Date:  2001-06       Impact factor: 3.725

Review 6.  Ofloxacin. A reappraisal of its use in the management of genitourinary tract infections.

Authors:  S V Onrust; H M Lamb; J A Balfour
Journal:  Drugs       Date:  1998-11       Impact factor: 9.546

7.  Comparative prophylactic efficacies of ciprofloxacin, ofloxacin, cefazolin, and vancomycin in experimental model of staphylococcal wound infection.

Authors:  D S Kernodle; A B Kaiser
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

8.  Pharmacokinetics and serum bactericidal titers of ciprofloxacin and ofloxacin following multiple oral doses in healthy volunteers.

Authors:  D Israel; J G Gillum; M Turik; K Harvey; J Ford; H Dalton; M Towle; R Echols; A H Heller; R Polk
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

Review 9.  The use of oral fluoroquinolones in nursing home patients.

Authors:  T M File; J S Tan
Journal:  Drugs Aging       Date:  1992 Jul-Aug       Impact factor: 3.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.